Mereo BioPharma Group plc - American Depositary Shares (MREO)
1.7700
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 21st, 4:33 AM EDT
Detailed Quote
Previous Close | 1.770 |
---|---|
Open | - |
Bid | 1.770 |
Ask | 1.780 |
Day's Range | N/A - N/A |
52 Week Range | 1.570 - 5.020 |
Volume | 1,302 |
Market Cap | 1.04B |
PE Ratio (TTM) | -25.29 |
EPS (TTM) | -0.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 4,193,246 |
Chart
About Mereo BioPharma Group plc - American Depositary Shares (MREO)
Mereo Biopharma Group is a biotechnology company focused on the development and commercialization of innovative therapeutics for patients with rare diseases and oncology. The company aims to address significant unmet medical needs by advancing a portfolio of product candidates that target specific conditions with potential for significant clinical impact. Mereo leverages both in-house research and strategic partnerships to bring new treatment options to market, enhancing the quality of life for impacted patients through novel therapeutic approaches. Their commitment encompasses all stages of drug development, from preclinical research through clinical trials and beyond. Read More
News & Press Releases
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 18, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · July 10, 2025
Via Benzinga · July 10, 2025
Via Benzinga · July 10, 2025
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · July 10, 2025
The study will continue onto a third and final analysis toward the end of the year.
Via Investor's Business Daily · July 10, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · July 10, 2025
Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.
Via Benzinga · July 10, 2025
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · July 10, 2025
Via Benzinga · July 10, 2025
Via Benzinga · July 10, 2025
Via Benzinga · July 10, 2025
The companies now expect final data from the Orbit and Cosmic studies by the end of the year.
Via Stocktwits · July 10, 2025
Via Benzinga · July 9, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · July 9, 2025
Data from Orbit and Cosmic studies expected around the end of the year
By Ultragenyx Pharmaceutical Inc. · Via GlobeNewswire · July 9, 2025

Via Benzinga · June 3, 2025

Via Benzinga · June 3, 2025
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)
By Mereo BioPharma Group plc · Via GlobeNewswire · May 13, 2025
Via Benzinga · March 27, 2025
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025
By Mereo BioPharma Group plc · Via GlobeNewswire · March 26, 2025

Uncover five promising stocks under $10, each poised for gains across diverse sectors for the second quarter of 2025.
Via MarketBeat · March 11, 2025

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT.
By Mereo BioPharma Group plc · Via GlobeNewswire · March 5, 2025

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025
By Mereo BioPharma Group plc · Via GlobeNewswire · January 12, 2025